Finance

Lists
Outlook: 71.2% bullish·1.9% bearish
Go to analysis
ABBV:NYSE
AbbVie Common Stock
266,69 USD
+0,36%
(+0,95) 1D
266,69 USD
0,00% (0,00)
After hours
Closed: 6-окт., 16:03:51 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABBV...
Open
267,74 USD
High
268,86 USD
Low
260,62 USD
Mkt. cap
466,06 млд
Avg. vol.
4,24 млн
Volume
4,50 млн
Dividend
2,59%
Quarterly dividend
1,73 USD
Ex-dividend date
2026-ж., 15-окт.
P/E ratio
75,43
52-wk high
269,39 USD
52-wk low
190,75 USD
EPS
3,54 USD
Beta
0,23
Shares outstanding
1,77 млд
No. of employees
57 миң
Open
267,74 USD
High
268,86 USD
Low
260,62 USD
Mkt. cap
466,06 млд
Avg. vol.
4,24 млн
Volume
4,50 млн
Dividend
2,59%
Quarterly dividend
1,73 USD
Ex-dividend date
2026-ж., 15-окт.
P/E ratio
75,43
52-wk high
269,39 USD
52-wk low
190,75 USD
EPS
3,54 USD
Beta
0,23
Shares outstanding
1,77 млд
No. of employees
57 миң
News stories
From web sources and news partners
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEORobert A. Michael
Employees57 миң
Founded2012-ж., 10-апр.
HeadquartersСевер Чикаго, Иллинойс, Америка Кошмо Штаттары
Sector-
Websiteabbvie.com
Analyst ratings
Based on 23 analysts giving stock ratings to ABBV in the past 3 months
Strong buy
Buy
19
Hold
4
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for ABBV in the last 3 months.
Highest
Current 266,69 USD
320,00 USD (+19,99%)
Average
283,57 USD (+6,33%)
Lowest
225,00 USD (-15,63%)
Analyst
Recommendation
Action
Price target
Projected
Date
Louise Chen
Scotiabank
Buy
Reiterated
320,00 USD
+20%
10/06/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
290,00 USD
+8,7%
09/28/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
300,00 USD
+12,5%
09/29/2026
Geoff Meacham
Citi
Hold
Maintained
260,00 USD
-2,5%
09/29/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
289,00 USD
+8,4%
10/01/2026
Tim Anderson
Bank of America Securities
Buy
Reiterated
289,00 USD
+8,4%
09/29/2026
Trung Huynh
RBC Capital
Buy
Maintained
280,00 USD
+5%
09/29/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/28/2026
Steve Scala
TD Cowen
Buy
Maintained
280,00 USD
+5%
09/28/2026
Chris Schott
J.P. Morgan
Buy
Maintained
285,00 USD
+6,9%
09/25/2026
David Amsellem
Piper Sandler
Buy
Reiterated
303,00 USD
+13,6%
09/23/2026
Luisa Hector
Berenberg Bank
Buy
Reiterated
275,00 USD
+3,1%
09/10/2026
Rajesh Kumar
HSBC
Buy
Maintained
315,00 USD
+18,1%
09/10/2026
William Katz
TD Cowen
Buy
Reiterated
280,00 USD
+5%
09/04/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
300,00 USD
+12,5%
08/17/2026
Alexandria Hammond
Wolfe Research
Buy
Upgraded
300,00 USD
+12,5%
08/13/2026
Emily Field
Barclays
Buy
Reiterated
300,00 USD
+12,5%
08/11/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Reiterated
260,00 USD
-2,5%
08/10/2026
Hans Engel
Erste Group
Buy
Upgraded
-
-
08/05/2026
Vamil Divan
Guggenheim
Buy
Reiterated
288,00 USD
+8%
08/03/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
296,00 USD
+11%
08/03/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
285,00 USD
+6,9%
07/31/2026
Courtney Breen
Bernstein
Hold
Maintained
225,00 USD
-15,6%
07/22/2026
Asad Haider
Goldman Sachs
Hold
Maintained
244,00 USD
-8,5%
07/21/2026
Michael Yee
UBS
Hold
Reiterated
260,00 USD
-2,5%
07/13/2026
Michael Harvey
RBC Capital
Buy
Reiterated
280,00 USD
+5%
07/10/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
280,00 USD
+5%
06/23/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
280,00 USD
+5%
06/23/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
250,00 USD
-6,3%
05/13/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
262,00 USD
-1,8%
04/20/2026
Nico Chen
DBS
Hold
Maintained
230,00 USD
-13,8%
02/25/2026
Last report
2026-ж., 31-июл.
Fiscal period
Q2 2026
EPS / Est. (USD)
3,65 USD / 3,61 USD
+1,08%beat
Revenue / Est. (USD)
16,99 млд / 16,76 млд
+1,36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
15,78 млд
16,62 млд
15,00 млд
16,99 млд
Cost of goods sold
4,46 млд
4,55 млд
4,22 млд
4,29 млд
Cost of revenue
4,46 млд
4,55 млд
4,22 млд
4,29 млд
Research and development expenses
2,29 млд
2,58 млд
2,47 млд
2,34 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,43 млд
3,82 млд
3,49 млд
3,55 млд
Operating expense
5,72 млд
6,40 млд
5,96 млд
5,90 млд
Total operating expenses
10,18 млд
10,95 млд
10,18 млд
10,19 млд
Operating income
5,60 млд
5,67 млд
4,82 млд
6,80 млд
Other non operating income
199,00 млн
120,00 млн
-3,00 млн
-55,00 млн
EBT including unusual items
714,00 млн
2,67 млд
1,04 млд
4,28 млд
EBT excluding unusual items
5,11 млд
5,12 млд
4,19 млд
6,07 млд
Income tax expense
526,00 млн
853,00 млн
342,00 млн
662,00 млн
Effective tax rate
73,67%
31,97%
32,92%
15,47%
Other operating expenses
-
-
-
-
Net income
186,00 млн
1,82 млд
695,00 млн
3,61 млд
Net profit margin
1,18%
10,93%
4,63%
21,27%
Earnings per share
1,86
2,71
2,65
3,65
Interest and investment income
72,00 млн
59,00 млн
72,00 млн
67,00 млн
Interest expense
-739,00 млн
-714,00 млн
-717,00 млн
-746,00 млн
Net interest expenses
-667,00 млн
-655,00 млн
-645,00 млн
-679,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
7,66 млд
7,66 млд
6,76 млд
8,68 млд
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору